These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1575207)

  • 1. Bone marrow and blood findings after marrow transplantation and rhGM-CSF therapy.
    Ryder JW; Lazarus HM; Farhi DC
    Am J Clin Pathol; 1992 May; 97(5):631-7. PubMed ID: 1575207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial.
    Lazarus HM; Andersen J; Chen MG; Variakojis D; Mansour EG; Oette D; Arce CA; Oken MM; Gerson SL
    Blood; 1991 Aug; 78(3):830-7. PubMed ID: 1859894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human interleukin-3 and recombinant human granulocyte-macrophage colony-stimulating factor administered in vivo after high-dose cyclophosphamide cancer chemotherapy: effect on hematopoiesis and microenvironment in human bone marrow.
    Orazi A; Cattoretti G; Schiró R; Siena S; Bregni M; Di Nicola M; Gianni AM
    Blood; 1992 May; 79(10):2610-9. PubMed ID: 1586713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GM-CSF therapy for delayed engraftment after autologous bone marrow transplantation.
    Brandwein JM; Nayar R; Baker MA; Sutton DM; Scott JG; Sutcliffe SB; Keating A
    Exp Hematol; 1991 Mar; 19(3):191-5. PubMed ID: 1995310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission.
    O'Day SJ; Rabinowe SN; Neuberg D; Freedman AS; Soiffer RJ; Spector NA; Robertson MJ; Anderson K; Whelan M; Pesek K
    Blood; 1994 May; 83(9):2707-14. PubMed ID: 8167349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer.
    Nemunaitis J; Rabinowe SN; Singer JW; Bierman PJ; Vose JM; Freedman AS; Onetto N; Gillis S; Oette D; Gold M
    N Engl J Med; 1991 Jun; 324(25):1773-8. PubMed ID: 1903847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma.
    Fay JW; Bernstein SH
    Semin Oncol; 1996 Apr; 23(2 Suppl 4):22-7. PubMed ID: 8600545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of a phase III study of recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid malignancies.
    Rabinowe SN; Neuberg D; Bierman PJ; Vose JM; Nemunaitis J; Singer JW; Freedman AS; Mauch P; Demetri G; Onetto N
    Blood; 1993 Apr; 81(7):1903-8. PubMed ID: 8461475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different response to recombinant human granulocyte-macrophage colony-stimulating factor in primary and secondary graft failure after bone marrow transplantation.
    Sierra J; Terol MJ; Urbano-Ispizua A; Rovira M; Marin P; Carreras E; Batlle M; Rozman C
    Exp Hematol; 1994 Jul; 22(7):566-72. PubMed ID: 8013572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of recombinant human granulocyte-macrophage colony stimulating factor for the treatment of delayed engraftment following high dose therapy and autologous hematopoietic stem cell transplantation for lymphoid malignancies.
    Vose JM; Bierman PJ; Kessinger A; Coccia PF; Anderson J; Oldham FB; Epstein C; Armitage JO
    Bone Marrow Transplant; 1991 Feb; 7(2):139-43. PubMed ID: 1675592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of granulocyte colony-stimulating factor following autologous bone marrow transplantation for non-Hodgkin's lymphoma with monoclonal antibody purged bone marrow.
    Schriber JR; Negrin RS; Chao NJ; Long GD; Horning SJ; Blume KG
    Leukemia; 1993 Oct; 7(10):1491-5. PubMed ID: 7692189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein versus granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for non-Hodgkin's lymphoma: results of a randomized double-blind trial.
    Vose JM; Pandite AN; Beveridge RA; Geller RB; Schuster MW; Anderson JE; LeMaistre CF; Ahmed T; Granena A; Keating A; Fernandez Ranada JM; Stiff PJ; Tabbara I; Longo W; Copelan EA; Nichols C; Smith A; Topolsky DL; Bierman PJ; Lebsack ME; Lange M; Garrison L
    J Clin Oncol; 1997 Apr; 15(4):1617-23. PubMed ID: 9193361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer: an economic analysis of a randomised, double-blind, placebo-controlled trial.
    Luce BR; Singer JW; Weschler JM; Buckner CD; Sheingold SH; Shannon-Dorcy K; Appelbaum FR; Nemunaitis J
    Pharmacoeconomics; 1994 Jul; 6(1):42-8. PubMed ID: 10172083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest.
    Haas R; Hohaus S; Egerer G; Ehrhardt R; Witt B; Hunstein W
    Bone Marrow Transplant; 1992 Jun; 9(6):459-65. PubMed ID: 1352717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granulocyte-macrophage colony-stimulating factor after autologous marrow transplantation for Hodgkin's disease.
    Klingemann HG; Wilkie-Boyd K; Rubin A; Onetto N; Nantel SH; Barnett MJ; Reece DE; Shepherd JD; Phillips GL
    Biotechnol Ther; 1994; 5(1-2):1-13. PubMed ID: 7703829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) following autologous marrow transplantation in man.
    Appelbaum FR; Nemunaitis J
    Behring Inst Mitt; 1988 Aug; (83):145-8. PubMed ID: 3071330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of recombinant human granulocyte-macrophage colony stimulating factor in autologous bone marrow transplantation.
    Nemunaitis J; Singer JW
    Am J Clin Oncol; 1991; 14 Suppl 1():S15-8. PubMed ID: 2048559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term in vivo priming of bone marrow haematopoiesis with rhG-CSF, rhGM-CSF or rhIL-3 before marrow harvest expands myelopoiesis but does not improve engraftment capability.
    Hansen PB; Knudsen H; Gaarsdal E; Jensen L; Ralfkiaer E; Johnsen HE
    Bone Marrow Transplant; 1995 Sep; 16(3):373-9. PubMed ID: 8535309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.